This trial is active, not recruiting.

Condition infected by chikungunya virus
Treatment sf36 (qqol)
Sponsor Centre Hospitalier Universitaire de Fort-de-France
Start date July 2014
End date January 2015
Trial size 200 participants
Trial identifier NCT02281123, 14/B/03, 2014-A00875-42


Chikungunya is a viral disease transmitted by mosquitoes whose clinical feature is the early joint damage. Approximately 8% of patients have chronic arthropathy resembling to the rheumatoid polyarthritis. The EchoCHIK study we propose is in the context of the epidemic in Martinique which began in January 2014. It should give a better understanding of arthritis and juxtaarticular of CHIK and look for signs that may allow ultrasound predict the evolution of chronic arthropathy of CHIK.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
sf36 (qqol)
use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)

Primary Outcomes

Presence of sonographic signs observed during the initial scan: periarticular infiltration, effusion, positive Doppler, erosions.
time frame: enrollement visit

Secondary Outcomes

Presence of clinical and sonographic signs observed at each visit: arthralgia, arthritis clinics, periarticular infiltration, effusion, positive Doppler erosions.
time frame: 1 month, 3 month, 6 month and 12 month after the first symptoms of infection by chikungunya virus

Eligibility Criteria

Male or female participants at least 45 years old.

Inclusion Criteria: 1. Age at onset of symptoms ≥ 45 years 2. Seen in consultation at the University Hospital of Fort-de-France 3. Suspected chikungunya infection (fever and sudden onset of joint pain affecting the wrists, hands, ankles or knees) 4. Duration of symptoms suggestive of infection chikungunya less than or equal to 10 days 5. Presence of joint pain on the day of inclusion 6. No history of inflammatory arthritis 7. Absence of steroidal or non-steroidal anti-inflammatory drugs taken within two weeks prior to inclusion 8. Ability to participate in the study throughout its duration (12 months) 9. Patient affiliated or beneficiary of a social health care. 10. Acceptance to participate in the study and monitoring proposed and signed informed consent Exclusion Criteria: 1. Age at onset of symptoms <45 years 2. Duration of symptoms suggestive of chikungunya for more than 10 days 3. Lack of joint pain on the day of inclusion 4. History of inflammatory arthritis Nonsteroidal anti-inflammatory drugs or 5. Taking in the two weeks preceding the inclusion 6. Inability to participate in the study throughout its duration (12 months) 7. Patient is not affiliated or beneficiary of a social health care. 8. Refusal to participate in the study or to sign a consent

Additional Information

Official title Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya
Principal investigator Lauren Brunier-Agot, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Centre Hospitalier Universitaire de Fort-de-France.